Mide Dışı Gastrointestinal Stromal Tümörlerin Yönetimi

Yazarlar

Gizem Güneş
https://orcid.org/0000-0001-5761-4052

Referanslar

Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S. vd. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 279(5350), 577-580. https://doi.org/10.1126/science.279.5350.577

Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N. vd. (2003). PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 299(5607), 708-710. https://doi.org/10.1126/science.1079666

Serrano, C., Martín-Broto, J., Asencio-Pascual, J. M., López-Guerrero, J. A., Rubió-Casadevall, J., Bagué, S. vd. (2023). 2023 GEIS Guidelines for gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology, 15, 17588359231192388. https://doi.org/10.1177/17588359231192388

Miettinen, M. ve Lasota, J. (2006). Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Seminars in Diagnostic Pathology, 23(2), 70-83. https://doi.org/10.1053/j.semdp.2006.09.001

Joensuu, H., Vehtari, A., Riihimäki, J., Nishida, T., Steigen, S. E., Brabec, P. vd. (2012). Risk of recurrence of gastrointestinal stromal tumour after surgery: An analysis of pooled population-based cohorts. The Lancet Oncology, 13(3), 265-274. https://doi.org/10.1016/S1470-2045(11)70299-6

Reith, J. D., Goldblum, J. R., Lyles, R. H. ve Weiss, S. W. (2000). Extragastrointestinal (soft tissue) stromal tumors: An analysis of 48 cases with emphasis on histologic predictors of outcome. Modern Pathology, 13(5), 577-585. https://doi.org/10.1038/modpathol.3880099

Agaimy, A. ve Wünsch, P. H. (2006). Gastrointestinal stromal tumours: A regular origin in the muscularis propria, but an extremely diverse gross presentation. A review of 200 cases to critically re-evaluate the concept of so-called extra-gastrointestinal stromal tumours. Langenbeck's Archives of Surgery, 391(4), 322-329. https://doi.org/10.1007/s00423-005-0005-5

Casali, P. G., Blay, J.-Y., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R. vd. (2022). Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 33(1), 20-33. https://doi.org/10.1016/j.annonc.2021.09.005

Hirota, S., Tateishi, U., Nakamoto, Y., Nishida, T., Okubo, K., Yamaguchi, U. vd. (2024). English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology. International Journal of Clinical Oncology, 29, 647-680. https://doi.org/10.1007/s10147-024-02488-1

Judson, I., Jones, R. L., Wong, N. A. C. S., Dileo, P., Bulusu, R., Smith, M. ve Almond, M. (2025). Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines. British Journal of Cancer, 132(1), 1-10. https://doi.org/10.1038/s41416-024-02672-0

Hirano, H., Naito, Y., Takahashi, T., Hirota, S., Kim, K.-M., Ryu, M.-H. vd. (2026). Updated Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor (2025). Gastric Cancer, 29, 887-903. https://doi.org/10.1007/s10120-026-01773-4

Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J. vd. (2002). Diagnosis of gastrointestinal stromal tumors: A consensus approach. Human Pathology, 33(5), 459-465. https://doi.org/10.1053/hupa.2002.123545

Liegl, B., Hornick, J. L., Corless, C. L. ve Fletcher, C. D. M. (2009). Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. American Journal of Surgical Pathology, 33(3), 437-446. https://doi.org/10.1097/PAS.0b013e318186b158

Lin, J., Liao, W., Wang, J., Li, W., Tang, X., Li, H. vd. (2023). Primary extra-gastrointestinal stromal tumor of retroperitoneum: Clinicopathologic characteristics and prognosis of six cases. Frontiers in Oncology, 13, 1033598. https://doi.org/10.3389/fonc.2023.1033598

Wang, S., Sun, F. ve Wang, X. (2025). Domestic research on extra-gastrointestinal stromal tumors: A ten-year review. Journal of Central South University. Medical Sciences, 50(2), 237-250. https://doi.org/10.11817/j.issn.1672-7347.2025.240044

Søreide, K., Sandvik, O. M., Søreide, J. A., Giljaca, V., Jureckova, A. ve Bulusu, V. R. (2016). Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiology, 40, 39-46. https://doi.org/10.1016/j.canep.2015.10.031

Miettinen, M., Kopczynski, J., Makhlouf, H. R., Sarlomo-Rikala, M., Gyorffy, H., Burke, A. vd. (2003). Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: A clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. American Journal of Surgical Pathology, 27(5), 625-641. https://doi.org/10.1097/00000478-200305000-00006

Miettinen, M., Makhlouf, H., Sobin, L. H. ve Lasota, J. (2006). Gastrointestinal stromal tumors of the jejunum and ileum: A clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. American Journal of Surgical Pathology, 30(4), 477-489. https://doi.org/10.1097/00000478-200604000-00008

Miettinen, M., Sarlomo-Rikala, M., Sobin, L. H. ve Lasota, J. (2000). Gastrointestinal stromal tumors and leiomyosarcomas in the colon: A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. American Journal of Surgical Pathology, 24(10), 1339-1352. https://doi.org/10.1097/00000478-200010000-00003

Miettinen, M. ve Sobin, L. H. (2001). Gastrointestinal stromal tumors in the appendix: A clinicopathologic and immunohistochemical study of four cases. American Journal of Surgical Pathology, 25(11), 1433-1437. https://doi.org/10.1097/00000478-200111000-00013

Miettinen, M., Furlong, M., Sarlomo-Rikala, M., Burke, A., Sobin, L. H. ve Lasota, J. (2001). Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: A clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. American Journal of Surgical Pathology, 25(9), 1121-1133. https://doi.org/10.1097/00000478-200109000-00002

Joensuu, H. (2008). Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Human Pathology, 39(10), 1411-1419. https://doi.org/10.1016/j.humpath.2008.06.025

D’Ambrosio, L., Fumagalli, E., Martino De Pas, T., Nannini, M., Bertuzzi, A., Carpano, S. vd. (2023). Guideline-based follow-up outcomes in patients with gastrointestinal stromal tumor with low risk of recurrence: A report from the Italian Sarcoma Group. JAMA Network Open, 6(11), e2341522. https://doi.org/10.1001/jamanetworkopen.2023.41522

Nishida, T., Hølmebakk, T., Raut, C. P. ve Rutkowski, P. (2019). Defining tumor rupture in gastrointestinal stromal tumor. Annals of Surgical Oncology, 26(6), 1669-1675. https://doi.org/10.1245/s10434-019-07297-9

McCarter, M. D., Antonescu, C. R., Ballman, K. V., Maki, R. G., Pisters, P. W. T., Demetri, G. D. vd. (2012). Microscopically positive margins for primary gastrointestinal stromal tumors: Analysis of risk factors and tumor recurrence. Journal of the American College of Surgeons, 215(1), 53-59. https://doi.org/10.1016/j.jamcollsurg.2012.05.008

Hølmebakk, T., Bjerkehagen, B., Hompland, I., Stoldt, S. ve Boye, K. (2019). Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour. British Journal of Surgery, 106(4), 419-426. https://doi.org/10.1002/bjs.11027

Robb, W. B., Bruyère, E., Amielh, D., Vinatier, E., Mabrut, J.-Y., Perniceni, T. vd. (2015). Esophageal gastrointestinal stromal tumor: Is tumoral enucleation a viable therapeutic option? Annals of Surgery, 261(1), 117-124. https://doi.org/10.1097/SLA.0000000000000505

Mohammadi, M., IJzerman, N. S., Hohenberger, P., Rutkowski, P., Jones, R. L., Gronchi, A. vd. (2021). Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. European Journal of Surgical Oncology, 47(8), 2173-2181. https://doi.org/10.1016/j.ejso.2021.03.234

Zhu, S., Guo, C., Zhang, J., Dai, N., Ullah, S., Liu, P., Fu, Y., Zhang, G., Zhang, F., Zhang, S. ve Cao, X. (2024). Optimal management options for esophageal gastrointestinal stromal tumors (E-GIST). European Journal of Surgical Oncology, 50(9), 108527. https://doi.org/10.1016/j.ejso.2024.108527

Zhou, Y., Peng, R., Chen, X., Xie, X., Chen, J. ve Li, R. (2025). The feasibility of endoscopic resection for esophageal gastrointestinal stromal tumor. Surgical Endoscopy, 39(6), 3718-3726. https://doi.org/10.1007/s00464-025-11763-9

Li, T. M., Kouanda, A. ve Adam, M. A. (2026). Defining the role of endoscopic resection for esophageal gastrointestinal stromal tumors. Journal of Gastrointestinal Oncology, 17(3), 188. https://doi.org/10.21037/jgo-2026-0205

Chok, A. Y., Koh, Y. X., Ow, M. Y. L., Allen, J. C. Jr. ve Goh, B. K. P. (2014). A systematic review and meta-analysis comparing pancreaticoduodenectomy versus limited resection for duodenal gastrointestinal stromal tumors. Annals of Surgical Oncology, 21(11), 3429-3438. https://doi.org/10.1245/s10434-014-3788-1

Lee, S. Y., Goh, B. K. P., Sadot, E., Rajeev, R., Balachandran, V. P., Gönen, M. vd. (2017). Surgical strategy and outcomes in duodenal gastrointestinal stromal tumor. Annals of Surgical Oncology, 24(1), 202-210. https://doi.org/10.1245/s10434-016-5565-9

Wu, L., Liu, M., Lin, X., Wang, C., Yang, Y., Fang, H. vd. (2024). Feasibility and efficacy of minimally invasive limited resection for primary duodenal gastrointestinal stromal tumors: A retrospective cohort study. BMC Surgery, 24, 126. https://doi.org/10.1186/s12893-024-02417-z

Sun, Y., Li, J., Wu, D., Tian, Y., Wang, R., Kuang, T. vd. (2025). The feasibility and safety of laparoscopic limited resection for duodenal gastrointestinal stromal tumor: A propensity score-matched analysis. Surgical Endoscopy, 39(12), 8064-8072. https://doi.org/10.1007/s00464-025-12088-3

Cavnar, M. J., Wang, L., Balachandran, V. P., Antonescu, C. R., Tap, W. D., Keohan, M. vd. (2017). Rectal gastrointestinal stromal tumor (GIST) in the era of imatinib: Organ preservation and improved oncologic outcome. Annals of Surgical Oncology, 24(13), 3972-3980. https://doi.org/10.1245/s10434-017-6087-9

Yang, W., Liu, Q., Lin, G., Zhang, B., Cao, H., Zhao, Y. vd. (2021). The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study. Journal of Surgical Oncology, 124(7), 1128-1135. https://doi.org/10.1002/jso.26628

Lam, T. J. R., Udonwa, S. A., Masuda, Y., Yeo, M. H. X., Farid Bin Harunal Ras, M. ve Goh, B. K. P. (2024). A systematic review and meta-analysis of neoadjuvant imatinib use in locally advanced and metastatic gastrointestinal stromal tumors. World Journal of Surgery, 48(7), 1681-1691. https://doi.org/10.1002/wjs.12210

Chen, J.-H., Cai, Z.-M., Yang, Z.-R., Lin, T., Hong, S.-C., Su, X.-C., Lin, Y.-M., Lin, L., Ye, Z.-S. ve Zhou, Y.-J. (2026). Comparative efficacy of neoadjuvant imatinib therapy in gastric versus rectal gastrointestinal stromal tumors: A two-center retrospective cohort study. BMC Gastroenterology, 26(1), 8. https://doi.org/10.1186/s12876-025-04467-w

Khan, S. I., O’Sullivan, N. J., Temperley, H. C., Rausa, E., Mehigan, B. J., McCormick, P., Larkin, J. O., Kavanagh, D. O. ve Kelly, M. E. (2023). Gastrointestinal stromal tumours (GIST) of the rectum: A systematic review and meta-analysis. Current Oncology, 30(1), 416-429. https://doi.org/10.3390/curroncol30010034

Wang, D., Zhang, Q., Blanke, C. D., Demetri, G. D., Heinrich, M. C., Watson, J. C. vd. (2012). Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of Radiation Therapy Oncology Group 0132. Annals of Surgical Oncology, 19(4), 1074-1080. https://doi.org/10.1245/s10434-011-2190-5

Joensuu, H., Eriksson, M., Sundby Hall, K., Reichardt, A., Hermes, B., Schütte, J. vd. (2020). Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: An analysis of a randomized clinical trial after 10-year follow-up. JAMA Oncology, 6(8), 1241-1246. https://doi.org/10.1001/jamaoncol.2020.2091

Blay, J.-Y., Schiffler, C., Bouché, O., Brahmi, M., Duffaud, F., Toulmonde, M. vd. (2024). A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. Annals of Oncology, 35(12), 1157-1168. https://doi.org/10.1016/j.annonc.2024.08.2343

Ford, S. J. ve Gronchi, A. (2016). Indications for surgery in advanced/metastatic GIST. European Journal of Cancer, 63, 154-167. https://doi.org/10.1016/j.ejca.2016.05.019

Yayınlanan

16 Kasım 2026

Lisans

Lisans